PharmaCyte Biotech, Inc. Appoints Raymond C.F. Tong, M.D. to the Board
October 10, 2017 at 08:30 am EDT
Share
The Board of Directors of PharmaCyte Biotech, Inc. appointed Raymond C.F. Tong, M.D. to the Board to fill a vacancy created by the departure of certain members of the Board. Dr. Tong will be a member of the Audit Committee of the Board. Dr. Tong serves as Chief Executive Officer of Harmony Medical Inc. He is also Chairman of the Business Development Committee of Shanghai Kedu Healthcare Group.
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
PHARMACYTE BIOTECH, INC. 
